Leisel Castelino serves as the Vice President of Global Product Management at Cepheid, where she leverages over 20 years of extensive experience in the molecular diagnostics industry to drive innovation and strategic growth. In her current role, Leisel is accountable for the global portfolio strategy...
Leisel Castelino serves as the Vice President of Global Product Management at Cepheid, where she leverages over 20 years of extensive experience in the molecular diagnostics industry to drive innovation and strategic growth. In her current role, Leisel is accountable for the global portfolio strategy and roadmap, ensuring that Cepheid remains at the forefront of diagnostic solutions across critical health areas such as respiratory diseases, oncology, sexual health, hospital-acquired infections (HAI), tuberculosis (TB), and virology. Her leadership of multifunctional teams is pivotal in fostering collaboration and alignment across various franchises, enabling the seamless execution of product innovation and sustainability initiatives.
Leisel has a proven track record in product launch and commercialization, successfully navigating the complexities of entering new markets while maximizing revenue and operational performance. Her expertise in market access and payer strategy allows her to formulate effective go-to-market strategies that resonate with stakeholders and drive adoption. By focusing on product lifecycle management and commercial planning, she ensures that each product not only meets market demands but also aligns with the overarching business objectives of Cepheid.
Key projects under her leadership include the development of cutting-edge diagnostic tools that address urgent public health needs, as well as initiatives aimed at enhancing product sustainability. Leisel’s ability to make strategic decisions and drive alignment within a cross-functional matrix has been instrumental in positioning Cepheid as a leader in the molecular diagnostics space, ultimately contributing to improved patient outcomes globally. Her commitment to continuous business performance and results-oriented approach exemplifies her dedication to advancing the field of diagnostics.
